Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13261
Abstract: The 3‐DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) has shown high sustained virologic response rates (~95%) in phase 3 clinical trials including >2300 HCV genotype 1–infected patients. Real‐world evidence… read more here.
Keywords: topaz topaz; long term; ombitasvir paritaprevir; genotype ... See more keywords